摘要
目的探讨孟鲁司特钠治疗小儿哮喘后气道炎症的动态变化及对肺功能的影响。方法选取2019年1月至2020年10月我院收治的100例哮喘患儿,随机分为基础组(50例,常规治疗)和干预组(50例,常规治疗联合孟鲁司特钠治疗)。比较两组患儿的疗效,治疗前及治疗2周后的IL-5、CRP、TNF-α、FEV1、PEF、FEV1/FVC水平。结果干预组的总有效率为98.00%,高于基础组的84.00%(P<0.05)。治疗2周后,两组的IL-5、CRP、TNF-α水平低于治疗前,FEV1、PEF、FEV1/FVC水平高于治疗前(P<0.05);干预组的IL-5、CRP、TNF-α水平低于基础组,FEV1、PEF、FEV1/FVC水平高于基础组(P<0.05)。结论孟鲁司特钠治疗小儿哮喘可提高临床疗效,显著改善患儿气道炎性指标及肺功能。
Objective To explore the dynamic changes of airway inflammation after montelukast sodium treatment in children with asthma and the influence on lung function.Methods 100 children with asthma admitted to our hospital from January 2019 to October 2020 were selected and randomly divided into basic group(50 cases,routine treatment)and intervention group(50 cases,routine treatment+montelukast sodium).The efficacy,and the levels of IL-5,CRP,TNF-α,FEV1,PEF and FEV1/FVC before treatment and after 2 weeks of treatment were compared between the two groups.Results The total effective rate of the intervention group was 98.00%,higher than84.00%of the basic group(P<0.05).After 2 weeks of treatment,the IL-5,CRP and TNF-αlevels of the two groups were lower than those before treatment,and the FEV1,PEF and FEV1/FVC levels were higher than those before treatment(P<0.05);The IL-5,CRP and TNF-αlevels of the intervention group were lower than those of the basic group,and the FEV1,PEF and FEV1/FVC levels were higher than those of the basic group(P<0.05).Conclusions Montelukast sodium in the treatment of children with asthma can improve the clinical efficacy,significantly improve the airway inflammatory indicators and lung function.
作者
张巧玲
王保进
ZHANG Qiaoling;WANG Baojin(Zhoukou Yongxing Hospital,Zhoukou 461400,China)
出处
《临床医学工程》
2021年第9期1215-1216,共2页
Clinical Medicine & Engineering
关键词
小儿哮喘
孟鲁司特钠
气道炎症
肺功能
Children with asthma
Montelukast sodium
Airway inflammation
Lung function
